PMS Tracker: Funds slump up to 10% in August; Valcreate, Ambit drag most while select portfolios advance

Several portfolio management service (PMS) funds logged sharp declines in August, with Valcreate Investment Managers’ Lifesciences and Specialty Opportunities strategy plunging 10.19%, the steepest among tracked portfolios, according to data from PMS Bazaar.

Ambit Investment Advisors’ Micro Marvels Portfolio and Money Grow Asset’s Small Midcap strategy also featured among the worst performers, each losing close to 9% during the month.

Accelt Asset’s Long Term Equity Fund declined 8.51%, Anand Rathi’s Impress PMS was down 8.28%, and Waya Financial Technologies’ Bin73 Sunrise Alpha slipped 8.24%. Avestha Fund’s Long Term Growth strategy fell 8.06%, Amaltas Asset’s Keystone Fund dropped 7.31%, and Square 64 Capital’s Multicap strategy declined 7.26%.

Motilal Oswal AMC’s India Growth Strategy shed 6.88%, Money Grow Asset’s Blend slipped 6.85%, Bonanza Portfolio’s Multicap fell 6.58%, and Valcreate’s Growing India strategy lost 6.49%. Several others, including portfolios from Badjate Wealth, Elever Investment, Ambit, PGIM India, Wallfort, Samvitti, and Alchemy Capital, ended the month lower by more than 5%.

Top performers: Wallfort, Valcreate, Right Horizons edge higher

Despite widespread losses, a handful of funds managed gains. Wallfort PMS’ Avenue Fund led the list with a 3.60% return. Valcreate’s IME Digital Disruption strategy followed with 2.84%, and Right Horizons’ Perennial fund gained 2.65%.

Wave Asset’s Pure Alpha added 2.14%, Maximal Capital’s Income Fund returned 2.13%, and Aequitas Investment’s India Opportunities Product advanced 2.05%. Other modest gainers included Pelican Holdings’ PE Fund, Shade Capital’s Value Fund, Ladderup Wealth’s Proud PMS, ithought Financial’s SPHERE, and Pace Financial’s Tresor Flexi, with returns between 0.9% and 2%.August underscored sharp divergence in PMS performance, with heavy losses across small and midcap strategies offset by modest gains in select multicap, thematic, and debt portfolios.Also read | Explained: What is China’s anti-involution shift and how it impacts Indian stocks(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)